SEC Filing Analysis: Johnson & Johnson (JNJ)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director received a small grant of Deferred Share Units (DSUs) as part of a standard compensation plan, deferring cash retainer fees. This is not an open-market transaction and has no trading significance.
• Market Impact: Neutral. The transaction is negligible in size and routine in nature.

Company Information

Field	Value
Company	JOHNSON & JOHNSON
Ticker Symbol	JNJ
CIK	0000200406
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Pinto Daniel E
CIK	0001555174
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-09
Transaction Code	A (Award)
Security Type	Deferred Share Units
Shares Involved	154.611
Price Per Share	$202.12
Total Value	$31,250.00
Shares Owned After	331.233
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$31,250.00
% of Market Cap	<0.00001%
Shares Transacted	154.611
% of Shares Outstanding	<0.00001%
Post-Transaction Ownership	331.233 DSUs (<0.00002% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $31,250 transaction value is insignificant for a company with a market capitalization of $472.05 billion.
• Ownership Concentration: The director's holdings remain negligible relative to the 2.4 billion shares outstanding.
• Dilution Impact: There is no dilution impact on common stock as these are cash-settled Deferred Share Units.

Additional Context

Transaction Notes

• Special Circumstances: The filing's footnotes clarify this transaction is an acquisition of DSUs for the deferral of a cash retainer under the company's Deferred Fee Plan for Directors. The units are settled in cash upon termination of the directorship, not in stock.